← FDA DRUG APPROVALS

FDA ANDA · ANDA072693

NORTREL 21 DAY

norethindrone and ethinyl estradiol

Sponsor: BARR

APPLICATION
ANDA072693
TYPE
ANDA
ORIGINAL APPROVAL
1992-02-28
LATEST ACTION
2022-04-29
ROUTE
ORAL, ORAL-21
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

NORTREL 1/35-21Prescription
ETHINYL ESTRADIOL 0.035MG, NORETHINDRONE 1MG · TABLET · ORAL-21

Approval history

2022-04-29Labeling · Supplement 32 · standardAP
2022-02-10Labeling · Supplement 27 · standardAP
2022-02-10Labeling · Supplement 28 · standardAP
2022-02-10Labeling · Supplement 26 · standardAP
2013-02-27Labeling · Supplement 24 · standardAP
2002-12-11Manufacturing (CMC) · Supplement 10AP
2001-12-04Manufacturing (CMC) · Supplement 13AP
2001-12-04Manufacturing (CMC) · Supplement 11AP
2001-08-22Manufacturing (CMC) · Supplement 9AP
2001-03-13Labeling · Supplement 8AP
2001-03-07Manufacturing (CMC) · Supplement 2AP
2001-03-07Manufacturing (CMC) · Supplement 5AP
2001-03-07Manufacturing (CMC) · Supplement 3AP
2001-03-07Labeling · Supplement 6AP
2001-03-07Manufacturing (CMC) · Supplement 4AP
1999-12-21Manufacturing (CMC) · Supplement 7AP
1992-02-28OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →